Bluejay Diagnostics Announces Reverse Stock Split
Bluejay Diagnostics (NASDAQ: BJDX) has announced a 1-for-50 reverse stock split effective November 18, 2024. The split will reduce outstanding common stock from approximately 27,624,740 shares to 552,854 shares. Trading will continue under the symbol 'BJDX' with a new CUSIP number 095633509. Stockholders will receive cash payments for fractional shares, and the split will proportionally adjust all outstanding equity awards and warrants. The company's transfer agent, Continental Stock Transfer & Trust Company, will manage the exchange process.
Bluejay Diagnostics (NASDAQ: BJDX) ha annunciato un raggruppamento azionario 1 per 50 che entrerà in vigore il 18 novembre 2024. Il raggruppamento ridurrà il numero di azioni ordinarie da circa 27,624,740 a 552,854. Le contrattazioni continueranno sotto il simbolo 'BJDX' con un nuovo numero CUSIP 095633509. I soci di minoranza riceveranno pagamenti in contanti per le azioni frazionarie e il raggruppamento modificherà proporzionalmente tutti i premi azionari e i warrant in essere. L'agente di trasferimento della società, la Continental Stock Transfer & Trust Company, gestirà il processo di scambio.
Bluejay Diagnostics (NASDAQ: BJDX) ha anunciado un split inverso de acciones de 1 por 50 que será efectivo el 18 de noviembre de 2024. El split reducirá las acciones ordinarias en circulación de aproximadamente 27,624,740 acciones a 552,854 acciones. La negociación continuará bajo el símbolo 'BJDX' con un nuevo número CUSIP 095633509. Los accionistas recibirán pagos en efectivo por las acciones fraccionarias y el split ajustará proporcionalmente todos los premios y warrants en circulación. El agente de transferencia de la empresa, Continental Stock Transfer & Trust Company, gestionará el proceso de intercambio.
블루제이 진단 (NASDAQ: BJDX)은 1 대 50 비율의 주식 분할을 2024년 11월 18일부터 시행한다고 발표했습니다. 이로 인해 약 27,624,740주의 보통주가 552,854주로 줄어듭니다. 거래는 'BJDX' 심볼 아래 계속 진행되며, 새로운 CUSIP 번호는 095633509입니다. 주주들은 분할된 주식에 대한 현금 지급을 받게 되며, 이번 분할은 모든 발행된 주식 보상 및 워런트를 비례적으로 조정합니다. 회사의 이전 에이전트인 Continental Stock Transfer & Trust Company가 교환 과정을 관리할 것입니다.
Bluejay Diagnostics (NASDAQ: BJDX) a annoncé un regroupement d'actions de 1 pour 50 qui entrera en vigueur le 18 novembre 2024. Le regroupement réduira le nombre d'actions ordinaires en circulation d'environ 27,624,740 actions à 552,854 actions. Les échanges continueront sous le symbole 'BJDX' avec un nouveau numéro CUSIP 095633509. Les actionnaires recevront des paiements en espèces pour les actions fractionnaires et le regroupement ajustera proportionnellement toutes les options et warrants en circulation. L'agent de transfert de la société, la Continental Stock Transfer & Trust Company, gérera le processus d'échange.
Bluejay Diagnostics (NASDAQ: BJDX) hat einen 1-zu-50 Rücksplit angekündigt, der am 18. November 2024 wirksam wird. Der Split wird die ausstehenden Stammaktien von etwa 27.624.740 Aktien auf 552.854 Aktien reduzieren. Der Handel wird unter dem Symbol 'BJDX' mit einer neuen CUSIP-Nummer 095633509 fortgesetzt. Aktionäre erhalten Barzahlungen für Bruchstücke von Aktien, und der Split wird alle ausstehenden Mitarbeiteraktienoptionen und Warrants proportional anpassen. Der Transferagent des Unternehmens, die Continental Stock Transfer & Trust Company, wird den Austauschprozess verwalten.
- None.
- Implementation of 1-for-50 reverse stock split indicates potential share price concerns
- Significant reduction in outstanding shares from 27.6M to 552.8K suggests possible Nasdaq compliance issues
Insights
The 1:50 reverse stock split is a significant corporate action aimed at maintaining NASDAQ listing compliance, which requires a minimum bid price of
The mechanical adjustment will multiply the stock price by 50 while proportionally reducing share count. However, reverse splits historically signal financial distress and often lead to continued downward pressure on stock price. Small-cap biotech companies typically pursue this strategy when facing delisting risks, which could impact trading liquidity and institutional investment potential.
ACTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-50 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on November 18, 2024, and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis on November 18, 2024 under the Company’s existing trading symbol, “BJDX.” At such time, the Company’s common stock will also commence trading with a new CUSIP number, 095633509.
At the effective time of the reverse stock split, every fifty (50) shares of Bluejay common stock issued and outstanding will be combined into one (1) share of common stock issued and outstanding, with no change to the par value of
The Company has retained its transfer agent, Continental Stock Transfer & Trust Company (“Continental”), to act as its exchange agent for the reverse stock split. Stockholders with shares held in certificate form will receive from Continental instructions regarding the exchange of their certificates. Stockholders that hold shares in book-entry form or hold their shares in brokerage accounts are not required to take any action and will see the impact of the reverse stock split reflected in their accounts, subject to brokers’ particular processes. Beneficial holders of Bluejay common stock are encouraged to contact their bank, broker, custodian or other nominee with questions regarding procedures for processing the reverse stock split.
About Bluejay Diagnostics:
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for triage and monitoring of disease progression. Bluejay’s first product candidate, an IL-6 Test for sepsis triage, is designed to provide accurate, reliable results in approximately 20 minutes from ‘sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.
Forward-Looking Statements:
This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements in this press release include, without limitation, the expected nature and timing of the Company’s planned FDA submission and related plans for clinical study amendment, whether the Company’s cash position will be sufficient to fund operations needed to achieve regulatory approval and initial commercialization of the Symphony IL-6 Test, whether such regulatory approval will actually occur and the continuation of the Company as a going concern. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest,” “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission, as updated by the Company’s subsequent Quarterly Reports on Form 10-Q. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events.
Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
neil.dey@bluejaydx.com
978-631-0310
FAQ
When will Bluejay Diagnostics (BJDX) reverse stock split take effect?
What is the ratio of BJDX reverse stock split?
How many shares will BJDX have after the reverse split?